Agios Pharmaceuticals Inc. (AGIO) announced after the close Thursday that it will no longer be developing its second pyruvate kinase-R activator, AG-519. The company has withdrawn its investigational new drug application after it was notified of a clinical hold by the FDA yesterday.
from RTT - Before the Bell http://ift.tt/2gRW6pj
via IFTTT
No comments:
Post a Comment